Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual MeetingFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in...